Review



angioquant version 1.33  (MathWorks Inc)


Bioz Verified Symbol MathWorks Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MathWorks Inc angioquant version 1.33
    Angioquant Version 1.33, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/angioquant+version+1%2E33/pmc07701684-121-1-4
    Average 90 stars, based on 1 article reviews
    angioquant version 1.33 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Software:

    Article Title: <p>In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin</p>
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.51 The antiangiogenic effect was then calculated using the following formula:52 Percentage inhibition 1⁄4 score of control vessels score of treated vessels score of control vessels � 100 Molecular Modeling Computational Tools Protein-Ligand docking was accomplished with the use of Autodock Vina 1.1.253 in Python Prescription (PyRx) software, installed in an iMac desktop computer, equipped with 3.1 GHz Intel Core i7 processor, 16GB RAM, and an NVIDIA GeForce 750M graphics card.

    Article Title: In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.

    Inhibition:

    Article Title: <p>In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin</p>
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.51 The antiangiogenic effect was then calculated using the following formula:52 Percentage inhibition 1⁄4 score of control vessels score of treated vessels score of control vessels � 100 Molecular Modeling Computational Tools Protein-Ligand docking was accomplished with the use of Autodock Vina 1.1.253 in Python Prescription (PyRx) software, installed in an iMac desktop computer, equipped with 3.1 GHz Intel Core i7 processor, 16GB RAM, and an NVIDIA GeForce 750M graphics card.

    Article Title: In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.

    Control:

    Article Title: <p>In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin</p>
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.51 The antiangiogenic effect was then calculated using the following formula:52 Percentage inhibition 1⁄4 score of control vessels score of treated vessels score of control vessels � 100 Molecular Modeling Computational Tools Protein-Ligand docking was accomplished with the use of Autodock Vina 1.1.253 in Python Prescription (PyRx) software, installed in an iMac desktop computer, equipped with 3.1 GHz Intel Core i7 processor, 16GB RAM, and an NVIDIA GeForce 750M graphics card.

    Article Title: In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin
    Article Snippet: Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified.



    Similar Products

    angioquant version 1.33  (MathWorks Inc)
    90
    MathWorks Inc angioquant version 1.33
    Angioquant Version 1.33, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/angioquant+version+1%2E33/pmc07701684-121-1-4
    Average 90 stars, based on 1 article reviews
    angioquant version 1.33 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    angioquant software version 1.33  (MathWorks Inc)
    90
    MathWorks Inc angioquant software version 1.33
    Statistical analysis of fold change in blood vessel documented using <t>angioquant</t> software:Increase in (A 1, 2, 3) length, (B 1,2,3) size and (C 1,2,3) Junction of blood vessel of the dorsal, cleft and ventral region in regenerated tail fin under hypoxia condition observed at 0dpa, 3dpa, 5dpa and 10dpa. At 3 dpa size of blood vessel increased by 1.4 fold in at dorsal, 1.3 fold in cleft and 1.5 fold in ventral regions. At 5dpa Size of the blood vessel showed fold increase of 1.8 times in dorsal region, 1.6 times in cleft and 1.7 in dorsal region of the caudal fin. Blood vessel length were found a fold increase of 2.3 in dorsal region 2.2 in cleft and 1.9 in ventral region, compared to normoxia, lacking signs of blood vessel development in regenerated tissue. at 10 dpa is significantly superior to control demonstrating a fold increase of 3.6 in length, 2.8 in junction and 2.6 in size (Fig.2) of the dorsal region compared to cleft region with fold increase at 3.5in length, 2.7in junction, 2.3 in size and ventral region with 2.8 in length, 2.7 in size and 2.1 in size of the blood vessel. The fold change is expressed as mean ± SEM. Statistical analyses performed using one-way ANOVA followed by Turkey’s multiple comparison tests for comparison between treatment values and control. P values < 0.05 considered to be statistically significant. ** P value <0.005, *** P value < 0.001, **** P value < 0.0001.
    Angioquant Software Version 1.33, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/angioquant+version+1%2E33/bio_rxiv__105767-52-12-16
    Average 90 stars, based on 1 article reviews
    angioquant software version 1.33 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Statistical analysis of fold change in blood vessel documented using angioquant software:Increase in (A 1, 2, 3) length, (B 1,2,3) size and (C 1,2,3) Junction of blood vessel of the dorsal, cleft and ventral region in regenerated tail fin under hypoxia condition observed at 0dpa, 3dpa, 5dpa and 10dpa. At 3 dpa size of blood vessel increased by 1.4 fold in at dorsal, 1.3 fold in cleft and 1.5 fold in ventral regions. At 5dpa Size of the blood vessel showed fold increase of 1.8 times in dorsal region, 1.6 times in cleft and 1.7 in dorsal region of the caudal fin. Blood vessel length were found a fold increase of 2.3 in dorsal region 2.2 in cleft and 1.9 in ventral region, compared to normoxia, lacking signs of blood vessel development in regenerated tissue. at 10 dpa is significantly superior to control demonstrating a fold increase of 3.6 in length, 2.8 in junction and 2.6 in size (Fig.2) of the dorsal region compared to cleft region with fold increase at 3.5in length, 2.7in junction, 2.3 in size and ventral region with 2.8 in length, 2.7 in size and 2.1 in size of the blood vessel. The fold change is expressed as mean ± SEM. Statistical analyses performed using one-way ANOVA followed by Turkey’s multiple comparison tests for comparison between treatment values and control. P values < 0.05 considered to be statistically significant. ** P value <0.005, *** P value < 0.001, **** P value < 0.0001.

    Journal: bioRxiv

    Article Title: Impact of hypoxia induced VEGF and its signaling during caudal fin regeneration in Zebrafish

    doi: 10.1101/105767

    Figure Lengend Snippet: Statistical analysis of fold change in blood vessel documented using angioquant software:Increase in (A 1, 2, 3) length, (B 1,2,3) size and (C 1,2,3) Junction of blood vessel of the dorsal, cleft and ventral region in regenerated tail fin under hypoxia condition observed at 0dpa, 3dpa, 5dpa and 10dpa. At 3 dpa size of blood vessel increased by 1.4 fold in at dorsal, 1.3 fold in cleft and 1.5 fold in ventral regions. At 5dpa Size of the blood vessel showed fold increase of 1.8 times in dorsal region, 1.6 times in cleft and 1.7 in dorsal region of the caudal fin. Blood vessel length were found a fold increase of 2.3 in dorsal region 2.2 in cleft and 1.9 in ventral region, compared to normoxia, lacking signs of blood vessel development in regenerated tissue. at 10 dpa is significantly superior to control demonstrating a fold increase of 3.6 in length, 2.8 in junction and 2.6 in size (Fig.2) of the dorsal region compared to cleft region with fold increase at 3.5in length, 2.7in junction, 2.3 in size and ventral region with 2.8 in length, 2.7 in size and 2.1 in size of the blood vessel. The fold change is expressed as mean ± SEM. Statistical analyses performed using one-way ANOVA followed by Turkey’s multiple comparison tests for comparison between treatment values and control. P values < 0.05 considered to be statistically significant. ** P value <0.005, *** P value < 0.001, **** P value < 0.0001.

    Article Snippet: Blood vessels were quantified in terms of length, junction and sprouting using angioquant software (Version 1.33, MathWorks).

    Techniques: Software, Control, Comparison